ImPassion132 does not meet the primary endpoint of PFS for the addition of atezeolizumab. Rebecca Dent #ESMOBreast24

Hematology Made Ridiculously Simple will be written by myself + Bloodman Book will be tailored towards med students, residents, and fellows. Also be useful for non physicians interested in hematology (pharma etc). The goal is to be very digestible, memorable, and funny.

JUST IN--> a much-needed new option for SMALL CELL LUNG CANCER (SCLC)==> U.S. FDA approval of Tarlatamab (bispecific T-cell engager binding DLL3 and CD3) for extensive-stage SCLC post platinum-based chemo. Approval based on DeLLphi-301 trial published in NEJM in 2023

< 2 weeks to #ASCO24, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #ESOPEC - #COMMIT - #INAVO120 - #DestinyBreast06 - #LAURA - #ADRIATIC - #NADINA - #MARIPOSA - #Amyloidosis #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter ASCO OncoAlert

Check out all the #ASCO24 #EdBook articles published to date! ascopubs.org/toc/edbk/curre… Current Volume | ASCO Educational Book

Next up IOV-COM-202 with front line data for #TIL + pembro in front line melanoma treatment. This is the lead up to the ongoing phase 3 #TILVANCE trial. #ASCO24 #Melanoma OncoAlert

Day 2 #ASCO24 highlights: 1. #INAVO120: Inavolesib mPIK3CA HR+ LA/mBC 2. #postMONARCH: Abema + Fulvestrant after CDK4/6i in mBC 3. #EMERALD: Eribulin + HP HER2 mBC 4. Favorable/V Favorable mRCC 5. #DREAMM7: BVd 2L Myeloma #bcsm #lcsm #mmsm #OncTwitter ASCO 1/10

Impressive increase in PFS with consolidation osimertinib after CRT for pts w unresectable stage III lung cancer. Crossover on progression 82% higher than in most other studies. OS far from mature. Will be adopted as a new standard where it is available I believe. #lcsm #ASCO24

🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves

Anyone still think we should not be using immune checkpoint inhibitors before surgery? Or that use of adjuvant ICI only is as good as neoadjuvant ICI? Phase 3 trial in resectable melanoma now in NEJM concurrent with plenary by Christian Blank #ASCO24 nejm.org/doi/full/10.10…

👏👏👏👏 #NADINA - Neoadj 2 cycles of ipi/nivo is better than adj 12x nivo! - pts with MPR did not receive adj IO: these pts did even better! - now we have to make this standard of care!!! Professor Georgina Long AO Christian Blank The Netherlands Cancer Institute The ASCO Post

Another home-run for lung cancer at #ASCO24: the #ADRIATIC trial in limited-stage SCLC. #Durvalumab as consolidation treatment significantly prolongs PFS (HR 0.76, 16.6 vs 9.2 mo.) and OS (HR 0.73, 55.9 vs 33.4 mo.) compared to placebo! ASCO OncoAlert

The treatment landscape for lower-risk MDS with anemia is rapidly changing! Check out this state of the art review by Dr Battaglia, Joe Cannova, Rafael Madero Marroquín, and myself where we cover natural hx of dz, trial endpoints & treatment strategies! #mdssm pubmed.ncbi.nlm.nih.gov/38814537/

PEARLY AC->T vs. AC -> Tcarbo among TNBC LN+ or 2cm 🔹7.2% ⬆️ in EFS w/ addition of carbo 🧐OS already very close to significant with 3.7% diff, p0.058 ☑️Very compelling data that pCR translates to outcome in TNBC #ASCO24 #bcsm

Neoadjuvant therapy asserting dominance #NADINA Phase 3 trial in resectable melanoma now in NEJM Masterful plenary ASCO Christian Blank #ASCO24 Congrats to all involved MarkFariesMD @ Professor Georgina Long AO The Netherlands Cancer Institute The Angeles Clinic Professor Richard Scolyer AO Melanoma Institute Australia

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro prnewswire.com/news-releases/…

#ICYMI: The treatment landscape for patients with resectable NSCLC has changed! My newly updated slide for our fellows. OncoAlert #lcsm #WCLC24

#MARIPOSA: Ph III, n= 1074, 1L Ami + lazertinib in EGFR mNSCLC - Ami + Laz now FDA Oncology approved in 1L - Improved PFS in ALL high risk features (HR: 0.49 to 0.71) from recent #ASCO24 #lcsm #onctwitter #MedTwitter

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Congratulations Sunny!!